Insmed

+58%

est. 2Y upside i

Healthcare

Rank

#870

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Insmed offers high potential upside from strong growth and pipeline catalysts, but entry at 28x revenue is rich.

Last updated: July 19, 2026

Bull (30%)+155%

If TPIP and other pipeline successes sustain high growth and multiple expands to 15x, equity value could reach ~$60B, a 155% return.

Base (50%)+36%

Multiple contracts toward public comps (8x) on projected revenue of ~$4B, yielding ~$32B valuation, a 36% return.

Bear (20%)-32%

Pipeline setbacks or competition compress multiple to 4x, valuation falls to ~$16B, a 32% loss.

Est. time to liquidity~3.0 years

Preference Stack Risk

low

Funding Intensity

No preference stack data available; likely low risk as company has revenue.

Dilution Risk

low

No recent funding rounds; dilution risk appears low given revenue base.

Secondary Liquidity

limited

Secondary market activity exists but limited details; liquidity may be constrained for employees.

Questions to Ask at the Interview

Strategic questions based on Insmed's data — designed to show you've done your homework.

1
“How does the company plan to diversify beyond ARIKAYCE to reduce single-product risk?”
2
“What is the cash runway, and does the company anticipate any near-term financing needs?”
3
“Given the high valuation, what is the expected timeline to liquidity for employees?”

Our model estimates +58% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.